Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

Building Your Care Team and Preparing for Visits

At a Glance

People with AKT2-related familial partial lipodystrophy benefit from coordinated care led by an experienced endocrinologist. Bring the complete genetic report, long-term glucose and lipid results, scans, and photos of fat-distribution changes to specialist visits.

Because AKT2-related disorders are so rare, you can be an informed partner and advocate on your own health team [1]. Most doctors will never have seen a case of AKT2 in their career. To ensure you receive the best care, you need a multidisciplinary team—a group of specialists who communicate with each other to manage the different ways your condition affects your body [2][3].

Ideally, your care should be coordinated by an endocrinologist who specializes in monogenic insulin resistance or lipodystrophy [1][4].

Building Your Care Team “Roster”

A comprehensive team for AKT2 usually includes the following specialists:

  • Lead Endocrinologist: This is your “quarterback.” They manage your blood sugar and overall metabolic health and should be familiar with rare insulin signaling disorders [1][4].
  • Medical Geneticist / Genetic Counselor: This specialist helps interpret your genetic report. They can explain whether your variant was inherited or occurred spontaneously, and provide genetic counseling for family screening. Note: Relatives should not be tested or reassured based solely on body shape or a Variant of Uncertain Significance (VUS) [5][6].
  • Specialized Dietitian: You need someone who understands that your diet isn’t about general “weight loss” but about managing triglycerides and energy spillover safely [7][8].
  • Hepatologist (Liver Specialist): Referred if needed to monitor for hepatic steatosis (fatty liver) and ensure it doesn’t progress to scarring [9][10].
  • Cardiologist: Referred if indicated to monitor your heart rhythm and screen for early signs of atherosclerosis (blocked arteries) [10][11].

Preparing for Your First Appointment

Your first visit with a specialist is the most important. To make the most of it, you should bring a “medical portfolio” that includes:

  1. The Genetic Report: This is your most critical document. It must show the exact AKT2 variant (e.g., p.Arg208Lys) and the laboratory’s classification of that variant [12][13].
  2. Longitudinal Lab Reports: Bring a history of your HbA1c, fasting glucose, and lipid panels (triglycerides and cholesterol) [3][14]. Seeing how these numbers have changed over years is more helpful than a single recent test [15].
  3. Body Composition Scans: If you have ever had a DXA scan (for bone density or body fat) or an ultrasound of your liver, bring the actual reports or images [2][16].
  4. A “Fat Distribution” Timeline: Be prepared to discuss when you first noticed changes in your body shape. Bringing older photographs can help the doctor see the progression of fat loss in your limbs or accumulation in your face and neck [14][15].

Vetting Your Specialists

Don’t be afraid to interview your doctors. A good specialist will welcome your engagement. You might ask:

  • “Have you ever treated a patient with a mutation in the AKT2 pathway before?”
  • “Are you comfortable managing patients who require very high doses of insulin or specialized medications like metreleptin?”
  • “How do you typically coordinate with other specialists for rare disease patients?”

If a doctor is unfamiliar with AKT2, you can ask if they are willing to consult with a national Lipodystrophy Center of Excellence to help guide your care [1][4]. These centers often act as a resource for local doctors managing rare metabolic conditions.

Common questions in this guide

Which specialists should be part of an AKT2-related lipodystrophy care team?
An endocrinologist with experience in monogenic insulin resistance or lipodystrophy can coordinate care. A medical geneticist or genetic counselor can interpret the AKT2 result, while a specialized dietitian helps with triglycerides and dietary fat; hepatology and cardiology may be added to monitor liver and heart health.
What should I bring to my first appointment for AKT2-related familial partial lipodystrophy?
Bring the complete genetic report, including the exact AKT2 variant and the laboratory’s classification. Also bring long-term HbA1c, fasting glucose, and lipid results, along with any body-composition or liver-scan reports and photos showing changes in fat distribution.
Why should a genetic counselor review my AKT2 genetic result?
A genetic counselor can explain what the variant means, whether it appears inherited or arose spontaneously, and whether family testing may be appropriate. Body shape alone or a variant of uncertain significance should not be used to test or reassure relatives.
How can I find clinicians who understand AKT2-related lipodystrophy?
Ask prospective clinicians whether they have treated AKT2 or other monogenic insulin-resistance conditions and how they coordinate rare-disease care. If local clinicians have limited experience, ask whether they will consult a national Lipodystrophy Center of Excellence.
What health problems should my AKT2-related lipodystrophy care team monitor?
Monitoring may include blood sugar, HbA1c, triglycerides and cholesterol, liver fat and scarring, heart rhythm, and signs of atherosclerosis. Your team can also discuss pancreatitis prevention, treatment needs, and how genetic results affect family screening.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with monogenic insulin resistance or rare AKT2-related conditions have you treated?
  2. 2.Are you familiar with the international consensus guidelines for lipodystrophy surveillance?
  3. 3.Can you help coordinate my care with specialists in hepatology and cardiology who have experience with rare metabolic disorders?
  4. 4.How will you incorporate my genetic testing results into my long-term treatment plan?
  5. 5.Do we have a dedicated dietitian who understands the specific fat-restriction needs of FPLD patients?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.

    Patni N, Chard C, Araújo-Vilar D, et al.

    Orphanet journal of rare diseases 2024; (19(1)):263 doi:10.1186/s13023-024-03245-3.

    PMID: 38992753
  2. 2

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  3. 3

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244
  4. 4

    Diagnostic and referral pathways in patients with rare lipodystrophy and insulin-resistance syndromes: key milestones assessed from a national reference center.

    Donadille B, Janmaat S, Mosbah H, et al.

    Orphanet journal of rare diseases 2024; (19(1)):177 doi:10.1186/s13023-024-03173-2.

    PMID: 38678257
  5. 5

    First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report.

    Holstein A, Jabri I, Linck JA, et al.

    Frontiers in endocrinology 2026; (17()):1855679 doi:10.3389/fendo.2026.1855679.

    PMID: 42440509
  6. 6

    Clinical Guidance for Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment.

    Gilio D, Foss-Freitas M, Oral EA

    Current diabetes reports 2025; (25(1)):47 doi:10.1007/s11892-025-01603-4.

    PMID: 40892266
  7. 7

    Partial lipodystrophy: Clinical presentation and treatment.

    Mosbah H, Vatier C, Vigouroux C

    Annales d'endocrinologie 2024; (85(3)):197-200 doi:10.1016/j.ando.2024.05.015.

    PMID: 38871513
  8. 8

    Influence of diet and body weight in treatment-resistant acquired partial lipodystrophy after hematopoietic stem cell transplantation and its potential for metabolic improvement.

    Ishida E, Horiguchi K, Matsumoto S, et al.

    Diabetology international 2024; (15(2)):290-296 doi:10.1007/s13340-023-00674-6.

    PMID: 38524924
  9. 9

    Waist circumference is independently associated with liver steatosis and fibrosis in LMNA-related and unrelated Familial Partial Lipodystrophy women.

    Viola LF, Valerio CM, Araujo-Neto JM, et al.

    Diabetology & metabolic syndrome 2023; (15(1)):182 doi:10.1186/s13098-023-01156-0.

    PMID: 37679847
  10. 10

    Rare Diagnosis of Familial Partial Lipodystrophy in a Patient With Life-Threatening Pancreatitis due to Hypertriglyceridemia.

    Akamnonu C, Ueda M, Shah A

    AACE clinical case reports 2022; (8(1)):11-14 doi:10.1016/j.aace.2021.06.005.

    PMID: 35097194
  11. 11

    Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease.

    Hussain I, Patni N, Garg A

    Pathology 2019; (51(2)):202-212 doi:10.1016/j.pathol.2018.11.004.

    PMID: 30595509
  12. 12

    Case Report: Familial partial lipodystrophy, description of novel and ultrarare variants with distinct phenotypic spectrum.

    Magno S, Pelosini C, Paoli M, et al.

    Frontiers in endocrinology 2026; (17()):1725771 doi:10.3389/fendo.2026.1725771.

    PMID: 41858864
  13. 13

    A series of genetically confirmed congenital lipodystrophy and diabetes in adult southern Indian patients.

    Rajan R, Chapla A, Johnson J, et al.

    Scientific reports 2024; (14(1)):28277 doi:10.1038/s41598-024-79516-7.

    PMID: 39550450
  14. 14

    Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?

    Vatier C, Vigouroux C, Mosbah H

    Annales d'endocrinologie 2024; (85(3)):190-194 doi:10.1016/j.ando.2024.05.019.

    PMID: 38871502
  15. 15

    A rapid action plan to improve diagnosis and management of lipodystrophy syndromes.

    Fourman LT, Lima JG, Simha V, et al.

    Frontiers in endocrinology 2024; (15()):1383318 doi:10.3389/fendo.2024.1383318.

    PMID: 38952397
  16. 16

    Anthropometric measurements as a key diagnostic tool for familial partial lipodystrophy in women.

    Veras VR, da Cruz Paiva Lima GE, da Ponte Melo I, et al.

    Diabetology & metabolic syndrome 2024; (16(1)):216 doi:10.1186/s13098-024-01413-w.

    PMID: 39227868

This page is for informational purposes only and does not constitute medical advice. It explains how to prepare for AKT2-related familial partial lipodystrophy care, but your endocrinologist, genetic counselor, and other clinicians should guide decisions about your specific situation.

Get notified when new evidence is published on AKT2-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.